Kajal Larson

588 total citations
25 papers, 477 citations indexed

About

Kajal Larson is a scholar working on Pharmacology, Epidemiology and Molecular Medicine. According to data from OpenAlex, Kajal Larson has authored 25 papers receiving a total of 477 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pharmacology, 13 papers in Epidemiology and 11 papers in Molecular Medicine. Recurrent topics in Kajal Larson's work include Antibiotics Pharmacokinetics and Efficacy (13 papers), Antibiotic Resistance in Bacteria (11 papers) and Pneumonia and Respiratory Infections (4 papers). Kajal Larson is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (13 papers), Antibiotic Resistance in Bacteria (11 papers) and Pneumonia and Respiratory Infections (4 papers). Kajal Larson collaborates with scholars based in United States, Belgium and Canada. Kajal Larson's co-authors include Edward P. Acosta, Elizabeth G. Rhee, Adedayo Adedoyin, Luzelena Caro, Matthew L. Rizk, Brian Yu, Laurent Chesnel, Yoshihiko Murata, Kun Wang and Alan Tita and has published in prestigious journals such as The Journal of Infectious Diseases, Antimicrobial Agents and Chemotherapy and American Journal of Obstetrics and Gynecology.

In The Last Decade

Kajal Larson

24 papers receiving 472 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kajal Larson United States	11	228	168	164	144	59	25	477
Maria Cusato Italy	13	333 1.5×	212 1.3×	297 1.8×	245 1.7×	51 0.9×	28	747
Alessio Mesini Italy	13	280 1.2×	147 0.9×	339 2.1×	101 0.7×	77 1.3×	49	662
Myrto Eleni Flokas United States	13	235 1.0×	76 0.5×	147 0.9×	209 1.5×	58 1.0×	20	605
Stéphane Paulus United Kingdom	16	338 1.5×	138 0.8×	89 0.5×	84 0.6×	81 1.4×	41	665
Yaakov Dickstein Israel	14	193 0.8×	104 0.6×	121 0.7×	155 1.1×	62 1.1×	24	622
Jean Li Yan United States	13	226 1.0×	238 1.4×	198 1.2×	234 1.6×	60 1.0×	28	546
Jung-Jr Ye Taiwan	15	170 0.7×	92 0.5×	155 0.9×	206 1.4×	59 1.0×	28	495
Bruno Viaggi Italy	17	249 1.1×	209 1.2×	113 0.7×	241 1.7×	57 1.0×	47	665
Ariadna Padullés Spain	11	227 1.0×	213 1.3×	84 0.5×	174 1.2×	16 0.3×	49	560
Patrick McLeroth United States	8	195 0.9×	239 1.4×	93 0.6×	331 2.3×	55 0.9×	12	554

Countries citing papers authored by Kajal Larson

Since Specialization

Citations

This map shows the geographic impact of Kajal Larson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kajal Larson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kajal Larson more than expected).

Fields of papers citing papers by Kajal Larson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kajal Larson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kajal Larson. The network helps show where Kajal Larson may publish in the future.

Co-authorship network of co-authors of Kajal Larson

This figure shows the co-authorship network connecting the top 25 collaborators of Kajal Larson. A scholar is included among the top collaborators of Kajal Larson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kajal Larson. Kajal Larson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bhavnani, Sujata M., Jeffrey Hammel, Alison Luckey, et al.. (2025). P-1251. Pharmacometric Analyses to Support Dose Selection of Zoliflodacin, a First-in-Class Oral Antibiotic Being Developed for the Treatment of Uncomplicated Gonorrhea. Open Forum Infectious Diseases. 12(Supplement_1).

Larson, Kajal, et al.. (2024). Population pharmacokinetic analyses for sulbactam–durlobactam using Phase 1, 2, and 3 data. Antimicrobial Agents and Chemotherapy. 69(1). e0048524–e0048524. 4 indexed citations

Larson, Kajal, et al.. (2023). 2549. Pharmacometric Analyses to Support Sulbactam-Durlobactam (SUL-DUR) Dosing Regimens in Patients with Altered Renal Function. Open Forum Infectious Diseases. 10(Supplement_2). 1 indexed citations

Nicolau, David P., Jan J. De Waele, Joseph L. Kuti, et al.. (2021). Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance. International Journal of Antimicrobial Agents. 57(4). 106299–106299. 27 indexed citations

Caro, Luzelena, David P. Nicolau, Jan J. De Waele, et al.. (2020). Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. Journal of Antimicrobial Chemotherapy. 75(6). 1546–1553. 52 indexed citations

Larson, Kajal, et al.. (2020). EDP-514, a novel pangenotypic class II hepatitis B virus core inhibitor: preliminary results of a phase 1 study in healthy adult subjects. Journal of Hepatology. 73. S871–S871. 1 indexed citations

Coakley, Eoin, Alaa Ahmad, Kajal Larson, et al.. (2019). LB6. EDP-938, a Novel RSV N-Inhibitor, Administered Once or Twice Daily Was Safe and Demonstrated Robust Antiviral and Clinical Efficacy in a Healthy Volunteer Challenge Study. Open Forum Infectious Diseases. 6(Supplement_2). S995–S995. 7 indexed citations

Larson, Kajal, Yogesh T. Patel, Susan Willavize, et al.. (2019). Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections. Antimicrobial Agents and Chemotherapy. 63(6). 30 indexed citations

Larson, Kajal, et al.. (2018). Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection. Journal of Infection and Chemotherapy. 25(3). 182–191. 11 indexed citations

10.

Bradley, John S., Jocelyn Y. Ang, Antonio Arrieta, et al.. (2018). Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection. The Pediatric Infectious Disease Journal. 37(11). 1130–1136. 33 indexed citations

11.

Daley, Peter, Thomas Louie, Sahil Khanna, et al.. (2017). Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial. Journal of Antimicrobial Chemotherapy. 72(12). 3462–3470. 62 indexed citations

12.

Larson, Kajal, John S. Bradley, Antonio Arrieta, et al.. (2017). Plasma Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Subjects with Cystic Fibrosis. Open Forum Infectious Diseases. 4(suppl_1). S295–S296. 4 indexed citations

13.

Boix, Vicente, Richard N. Fedorak, Kathleen M. Mullane, et al.. (2017). Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection. Open Forum Infectious Diseases. 4(1). ofw275–ofw275. 64 indexed citations

14.

Larson, Kajal, Matthew G. Johnson, Matthew L. Rizk, et al.. (2017). Ceftolozane/Tazobactam Dose Evaluation for Pediatric Subjects with Complicated Intra-Abdominal Infection and Complicated Urinary Tract Infection. Open Forum Infectious Diseases. 4(suppl_1). S528–S529. 2 indexed citations

15.

Le, Vien T. M., Kajal Larson, Shawn D. Flanagan, et al.. (2017). Effects of Tedizolid Phosphate on Survival Outcomes and Suppression of Production of Staphylococcal Toxins in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Necrotizing Pneumonia. Antimicrobial Agents and Chemotherapy. 61(4). 14 indexed citations

16.

Sutton, Amelia, et al.. (2015). Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis. American Journal of Obstetrics and Gynecology. 212(6). 812.e1–812.e6. 46 indexed citations

17.

Larson, Kajal, Tim R. Cressey, Ram Yogev, et al.. (2015). Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults. Journal of the Pediatric Infectious Diseases Society. 5(2). 131–137. 8 indexed citations

18.

Larson, Kajal, et al.. (2014). Pharmacokinetic Enhancers in HIV Therapeutics. Clinical Pharmacokinetics. 53(10). 865–872. 50 indexed citations

19.

Acosta, Edward P., Peta L. Grigsby, Kajal Larson, et al.. (2013). Transplacental Transfer of Azithromycin and Its Use for Eradicating Intra-amniotic Ureaplasma Infection in a Primate Model. The Journal of Infectious Diseases. 209(6). 898–904. 37 indexed citations

20.

Acosta, Edward P., Kajal Larson, & Jennifer P. King. (2013). Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics. Adolescent Health Medicine and Therapeutics. 4. 79–79. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact